Myovant

News

Sumitomo ups ante and wins support for Myovant takeover

A sweetened offer from Sumitomo Pharma has convinced endocrinology specialist Myovant to agree to a takeover, after its first was rejected.

News

ObsEva files uterine fibroid drug in US, chasing AbbVie, Myo...

Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number of women eligible for this type of

News

FDA clears Myovant's relugolix for uterine fibroids, setting...

Myovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first once-daily oral drug in the US to treat heavy menstrual bleeding associated with ut

News

Birth control pills on calendar (add vignette tone)

Pfizer/Myovant take relugolix contraceptive combination pill...

Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of a contraceptive combination tablet.

Sumitomo ups ante and wins support for Myovant takeover

ObsEva files uterine fibroid drug in US, chasing AbbVie, Myo...

FDA clears Myovant's relugolix for uterine fibroids, setting...

Pfizer/Myovant take relugolix contraceptive combination pill...

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

Myovant

Editor's Picks